Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer

26 Jun 2014

Abstract excerpt

Triple-negative breast cancer (TNBC) is a highly heterogeneous and recurrent subtype of breast cancer that lacks an effective targeted therapy. To identify candidate therapeutic targets, we profiled global gene expression in TNBC and breast tumor-initiating cells with a patient survival dataset. Eight TNBC-related kinases were found to be overexpressed in TNBC cells with stem-like properties. Among them,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer Cells and Metastasis
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24970481
DOI: 10.1158/0008-5472.can-14-0584

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast CancerPMID 24970481Read ↗

Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancerSemantic proximity Read ↗

Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC).Semantic proximity Read ↗

Divide and Conquer—Targeted Therapy for Triple-Negative Breast CancerSemantic proximity Read ↗

New Biomarkers and Treatment Advances in Triple-Negative Breast CancerSemantic proximity Read ↗

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.Semantic proximity Read ↗

Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative Breast CancerSemantic proximity Read ↗

Triple-negative breast cancer and the need for new therapeutic targets.Semantic proximity Read ↗

Molecular subtypes and precision treatment of triple-negative breast cancerSemantic proximity Read ↗

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast CancerSemantic proximity Read ↗

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting a cell state common to triple‐negative breast cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.